Xeloda & Palmar-plantar erythrodysaesthesia syndrome

6.7%

of users reported Palmar-plantar erythrodysaesthesia syndrome

73.1%

also reported Severe reaction

73.9%

are women

Severe reaction

73.1%

Hospitalization

13.8%

Death

7.5%

Disability

4.4%

Life-threatening condition

1.2%

Xeloda: general information

20 - 29 years

0.6%

30 - 39 years

4.7%

40 - 49 years

13.0%

50 - 59 years

26.2%

60 - 69 years

30.3%

70 - 79 years

19.2%

80 - 89 years

5.7%

90 - 99 years

0.2%